| Description | Zalcitabine (Dideoxycytidine)(Dideoxycytidine;ddC; 2', 3'-Dideoxycytidine) is a nucleoside analog reverse transcriptase inhibitor (NRTI); At low concentrations, It can potently inhibit HIV replication by binding to reverse transcriptase terminated synthesis of viral DNA chain. |
| In vitro | Zalcitabine是一种双脱氧核苷类抗逆转录病毒药物，在未感染细胞和感染艾滋病毒的细胞中都会磷酸化成活性代谢物 2',3'-双脱氧胞苷 5'-三磷酸酯（ddCTP）。在治疗浓度下，ddCTP 可通过抑制逆转录酶和终止前病毒 DNA 链的延伸来抑制 HIV 的复制[1]。Zalcitabine对 CHO/hOAT1 细胞摄取 [3H]-PAH 具有抑制作用，IC50 值为 1.23 mM。此外，随着 CHO/hOAT1 细胞中 hOATI 活性的增强，细胞对Zalcitabine的吸收增加了三倍[2]。 |
| Synonyms | Dideoxycytidine, ddC, 扎西他滨, NSC 606170, Ro 24-2027/000, 2',3'-Dideoxycytidine |
| molecular weight | 211.22 |
| Molecular formula | C9H13N3O3 |
| CAS | 7481-89-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (284.06 mM), Sonication is recommended. |
| References | 1. Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80. 2. Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2. |